Precigen (PGEN) EBITDA Margin (2012 - 2026)
Precigen (PGEN) reported EBITDA Margin of 25.78% for Q1 2026, up 165923.0% year-over-year from N/an in Q1 2025, and up 94.57% quarter-over-quarter from 474.61% in Q4 2025.
Precigen (PGEN) EBITDA Margin (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of EBITDA Margin data on file, last reported at 25.78% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 25.78%, up 165923.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 337.17% (up 272736.0% YoY), and the FY2025 annual result was 1141.13%, up 229910.0% from the prior year.
- EBITDA Margin climbed to 25.78% in Q1 2026 per PGEN's latest filing, from 474.61% in the prior quarter.
- Over five years, EBITDA Margin peaked at 152.32% in Q4 2022 and troughed at 2093700.0% in Q3 2023.
- A 5-year average of 139571.95% and a median of 1827.85% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 209326491 bps in 2023, then jumped 209130023 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 152.32% in 2022, then plunged by 1930 bps to 2786.97% in 2023, then rose by 29 bps to 1970.7% in 2024, then surged by 76 bps to 474.61% in 2025, then surged by 95 bps to 25.78% in 2026.
- Business Quant data shows PGEN's EBITDA Margin at 25.78% in Q1 2026, 474.61% in Q4 2025, and 93423.53% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | -25.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.78% |
| Dec 31, 2025 | -474.61% |
| Jun 30, 2025 | -93,423.53% |
| Mar 31, 2025 | -1,685.01% |
| Dec 31, 2024 | -1,970.70% |
| Sep 30, 2024 | -2,399.77% |
| Jun 30, 2024 | -9,040.27% |
| Mar 31, 2024 | -17,688.41% |
| Dec 31, 2023 | -2,786.97% |
| Sep 30, 2023 | -2,093,700.00% |
| Jun 30, 2023 | -1,195.25% |
| Mar 31, 2023 | -7,246.30% |
| Dec 31, 2022 | 152.32% |
| Sep 30, 2022 | -435.09% |
| Jun 30, 2022 | -830.02% |
| Mar 31, 2022 | -401.83% |
| Dec 31, 2021 | 214.33% |
| Sep 30, 2021 | -645.96% |
| Jun 30, 2021 | -687.18% |
| Mar 31, 2021 | -72.16% |